What Imunon Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 3 | 6 |
| Total trades | 28 | 53 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 130,432 | 349,742 |
| Disposed | 7,515 | 22,385 |
| Net activity | +122,917 | +327,357 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Tardugno Michael H | Executive Chairman of Board | Oct 09 | Grant / award · A | +7,800 | $1.08 | +$8.42K | 111,721 |
| Lindborg Stacy | President and CEO | Oct 09 | Grant / award · A | +2,977 | $1.08 | +$3.22K | 116,174 |
| Faller Douglas Vincent | Chief Medical Officer | Oct 09 | Grant / award · A | +1,249 | $1.08 | +$1.35K | 46,927 |
| Lindborg Stacy | President and CEO | Sep 25 | Grant / award · A | +6,697 | $1.41 | +$9.44K | 113,197 |
| Tardugno Michael H | Executive Chairman of Board | Sep 25 | Grant / award · A | +7,169 | $1.41 | +$10.1K | 103,921 |
| Faller Douglas Vincent | Chief Medical Officer | Sep 25 | Grant / award · A | +4,390 | $1.41 | +$6.19K | 45,678 |
| Faller Douglas Vincent | Chief Medical Officer | Sep 11 | Grant / award · A | +4,211 | $1.47 | +$6.19K | 41,288 |
| Tardugno Michael H | Executive Chairman of Board | Sep 11 | Grant / award · A | +5,824 | $1.47 | +$8.56K | 95,699 |
| Lindborg Stacy | President and CEO | Sep 11 | Grant / award · A | +5,504 | $1.47 | +$8.09K | 105,580 |
| Eylward Susan | General Counsel and Corp Sec | Aug 31 | Open-market sale · S | −2,525 | $1.56 | −$3.95K | 2,896 |
| Tardugno Michael H | Executive Chairman of Board | Aug 28 | Grant / award · A | +7,371 | $1.60 | +$11.8K | 89,875 |
| Lindborg Stacy | President and CEO | Aug 28 | Grant / award · A | +6,822 | $1.60 | +$10.9K | 100,076 |
| Eylward Susan | General Counsel and Corp Sec | Aug 28 | Grant / award · A | +2,525 | $1.60 | +$4.04K | 5,421 |
| Faller Douglas Vincent | Chief Medical Officer | Aug 28 | Grant / award · A | +3,626 | $1.60 | +$5.8K | 37,077 |
| Eylward Susan | General Counsel and Corp Sec | Aug 17 | Open-market sale · S | −2,449 | $1.63 | −$3.99K | 2,896 |
| Lindborg Stacy | President and CEO | Aug 14 | Grant / award · A | +6,615 | $1.65 | +$10.9K | 93,254 |
| Faller Douglas Vincent | Chief Medical Officer | Aug 14 | Grant / award · A | +3,516 | $1.65 | +$5.8K | 33,451 |
| Eylward Susan | General Counsel and Corp Sec | Aug 14 | Grant / award · A | +2,449 | $1.65 | +$4.04K | 5,345 |
| Tardugno Michael H | Executive Chairman of Board | Aug 14 | Grant / award · A | +7,147 | $1.65 | +$11.8K | 82,504 |
| Eylward Susan | General Counsel and Corp Sec | Aug 03 | Open-market sale · S | −2,541 | $1.57 | −$3.98K | 2,896 |
Loading...
